muscle weakness; liver function parameters increased; creatine kinase increased; renal function parameter increased; fatigue; muscle pain; this is a spontaneous report received from a contactable reporter(s) (physician) from the regulatory authority web. regulatory number: at-basgages-2021-076920 . a 42 year-old female patient received bnt162b2 (comirnaty), intramuscular, administration date 09dec2021 (lot number: fk6303) as dose 2, single for covid-19 immunisation. the patient's relevant medical history was not reported. there were no concomitant medications. vaccination history included: comirnaty (dose 1), administration date: 18nov2021, for covid-19 vaccination. the following information was reported: muscular weakness (medically significant) with onset 10dec2021, outcome "not recovered", described as "muscle weakness"; hepatic enzyme increased (medically significant) with onset 10dec2021, outcome "not recovered", described as "liver function parameters increased"; blood creatine phosphokinase increased (medically significant) with onset 10dec2021, outcome "not recovered", described as "creatine kinase increased"; renal function test abnormal (medically significant) with onset 10dec2021, outcome "not recovered", described as "renal function parameter increased"; fatigue (non-serious) with onset 10dec2021, outcome "not recovered", described as "fatigue"; myalgia (non-serious) with onset 10dec2021, outcome "not recovered", described as "muscle pain". the patient underwent the following laboratory tests and procedures: blood creatine phosphokinase: increased; hepatic enzyme: increased; renal function test abnormal: increased. no follow-up attempts are possible. no further information is expected

test name: creatine kinase; result unstructured data: test result:increased; test name: liver enzymes; result unstructured data: test result:increased; test name: renal test; result unstructured data: test result:increased

na

na